3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
205
Carcinoma, Non-Small-Cell Lung
130
Neoplasms
101
Neoplasm Metastasis
70
Breast Neoplasms
66
Ovarian Neoplasms
42
Urinary Bladder Neoplasms
37
Lung Neoplasms
37
Triple Negative Breast Neoplasms
34
Colorectal Neoplasms
30
Lymphoma, Large B-Cell, Diffuse
29
Cholangiocarcinoma
28
Biliary Tract Neoplasms
27
Carcinoma, Transitional Cell
23
Lymphoma, Non-Hodgkin
22
Adenocarcinoma
22
Recurrence
21
Lymphoma
20
Fallopian Tube Neoplasms
18
Stomach Neoplasms
15
Sarcoma
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Non-Muscle Invasive Bladder Neoplasms
13
Carcinoma, Pancreatic Ductal
13
Nasopharyngeal Carcinoma
12
Gallbladder Neoplasms
12
Bile Duct Neoplasms
11
Melanoma
10
Carcinoma
10
Solid Tumors
9
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Sunitinib
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Gemcitabine
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Diseases
×
Gemcitabine
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled